Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
1 "Chang Yoon Woo"
Filter
Filter
Article category
Keywords
Publication year
Authors
Case Report
Sunitinib Treatment for Metastatic Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease
Ho Cheol Kim, Jung Su Lee, Sang Hyung Kim, Hoon Sub So, Chang Yoon Woo, Jae Lyun Lee
Cancer Res Treat. 2013;45(4):349-353.   Published online December 31, 2013
DOI: https://doi.org/10.4143/crt.2013.45.4.349
AbstractAbstract PDFPubReaderePub
Von Hippel-Lindau (VHL) disease is an autosomal dominant disease that produces a variety of tumors and cysts in the central nervous system and visceral organs, including renal cell carcinoma (RCC). RCC in patients with VHL disease does not frequently metastasize, therefore, the response to treatment and prognosis of metastatic RCC developed in patients with VHL disease has not been reported. Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor with antiangiogenic and antitumor activity. Here, we report on four patients with metastatic RCC in VHL disease who received sunitinib and achieved partial responses that have lasted for a prolonged period of time.

Citations

Citations to this article as recorded by  
  • The Clinical and Molecular Features in the VHL Renal Cancers; Close or Distant Relatives with Sporadic Clear Cell Renal Cell Carcinoma?
    Alessandra Cinque, Roberto Minnei, Matteo Floris, Francesco Trevisani
    Cancers.2022; 14(21): 5352.     CrossRef
  • Hereditary renal cell tumors: Clinicopathologic importance
    Harmanjot Singh, Mukul K. Divatia, Donghwa Baek, Jae Y. Ro
    annals of urologic oncology.2021;[Epub]     CrossRef
  • Von Hippel-Lindau Disease: Current Challenges and Future Prospects


    Sven Gläsker, Evelynn Vergauwen, Christian A Koch, Alexander Kutikov, Alexander O Vortmeyer
    OncoTargets and Therapy.2020; Volume 13: 5669.     CrossRef
  • The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma
    Song Peng, Jun Zhang, Xintao Tan, Yiqiang Huang, Jing Xu, Natalie Silk, Dianzheng Zhang, Qiuli Liu, Jun Jiang
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
  • Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights
    Maria I. Carlo, A. Ari Hakimi, Grant D. Stewart, Gennady Bratslavsky, James Brugarolas, Ying-Bei Chen, W. Marston Linehan, Eamonn R. Maher, Maria J. Merino, Kenneth Offit, Victor E. Reuter, Brian Shuch, Jonathan A. Coleman
    European Urology.2019; 76(6): 754.     CrossRef
  • The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel–Lindau Disease: A Retrospective Study of 32 Patients
    Kaifang Ma, Baoan Hong, Jingcheng Zhou, Yanqing Gong, Jiangyi Wang, Shengjie Liu, Xiang Peng, Bowen Zhou, Jiufeng Zhang, Haibiao Xie, Kenan Zhang, Lei Li, Desheng Cai, Zixin Wang, Lin Cai, Kan Gong
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease
    Gang Yuan, Qiuli Liu, Dali Tong, Gaolei Liu, Yuting Yi, Jun Zhang, Yao Zhang, Lin-ang Wang, Luofu Wang, Rongrong Chen, Yanfang Guan, Xin Yi, Weihua Lan, Jun Jiang
    Cancer Biology & Therapy.2018; 19(9): 766.     CrossRef
  • Genetic Predisposition to Renal Cell Carcinoma: Implications for Counseling, Testing, Screening, and Management
    Brian Shuch, Jin Zhang
    Journal of Clinical Oncology.2018; 36(36): 3560.     CrossRef
  • A Case of von Hippel–Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas
    Su Jin Heo, Choong-kun Lee, Kyu Yeon Hahn, Gyuri Kim, Hyuk Hur, Sung Hoon Choi, Kyung Seok Han, Arthur Cho, Minkyu Jung
    Cancer Research and Treatment.2016; 48(1): 409.     CrossRef
  • Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease
    Akihiro Kobayashi, Masanobu Takahashi, Hiroo Imai, Shoko Akiyama, Shunsuke Sugiyama, Keigo Komine, Ken Saijo, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota, Naomi Sato, Fumiyoshi Fujishima, Taro Shuin, Hideki Shimodaira, Chikashi Ishioka
    Internal Medicine.2016; 55(6): 629.     CrossRef
  • Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group
    Stéphane Oudard, Reza Elaidi, Mara Brizard, Céline Le Rest, Valérie Caillet, Sophie Deveaux, Gérard Benoit, Jean-Michel Corréas, Farida Benoudiba, Philippe David, Alain Gaudric, Pascal Hammel, Dominique Joly, Marc Olivier Timsit, Arnaud Méjean, Stéphane R
    Oncotarget.2016; 7(51): 85306.     CrossRef
  • Pharmacogenomic biomarkers for personalized cancer treatment
    C. Rodríguez‐Antona, M. Taron
    Journal of Internal Medicine.2015; 277(2): 201.     CrossRef
  • Pharmacological HIF2α inhibition improves VHL disease–associated phenotypes in zebrafish model
    Ana Martins Metelo, Haley R. Noonan, Xiang Li, Youngnam Jin, Rania Baker, Lee Kamentsky, Yiyun Zhang, Ellen van Rooijen, Jordan Shin, Anne E. Carpenter, Jing-Ruey Yeh, Randall T. Peterson, Othon Iliopoulos
    Journal of Clinical Investigation.2015; 125(5): 1987.     CrossRef
  • Molecular and immunologic markers of kidney cancer—potential applications in predictive, preventive and personalized medicine
    Amanda Mickley, Olga Kovaleva, Julia Kzhyshkowska, Alexei Gratchev
    EPMA Journal.2015;[Epub]     CrossRef
  • 12,080 View
  • 70 Download
  • 15 Web of Science
  • 14 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP